Newleos secures $93.5m for neuropsychiatric treatments
Newleos Therapeutics has closed an oversubscribed Series A financing round, raising $93.5m to revolutionise neuropsychiatric disorder treatments with new medicines.…
Central Nervous System
-
-
SmartCella gains rights to advance cell therapy research for Parkinson’s
SmartCella has secured exclusive rights to advance research into cell replacement therapies for the treatment of Parkinson's disease (PD). The…
-
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’…
-
USC receives grant for gene therapy targeting glioblastoma
The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to…
-
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing
The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's Leqembi (lecanemab-irmb)…
-
Acadia submits MAA to EMA for Rett syndrome therapy
Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for trofinetide, aimed at treating…
-
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi…
-
Neumora shares sink following Phase III flop in MDD
Neumora Therapeutics saw a drop of more than 80% in its share price following the announcement of a Phase III…
-
Astellas and Sangamo sign capsid deal for neurological diseases
Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at…
-
Reprieve for WuXi as Biosecure vote likely pushed to 2025
The Biosecure Act was left out of a key US defence bill that passed in the House last week, in…
